All In MedTech

Device Trial Radar · NCT06867315

Transperineal Irreversible Electroporation for Benign Prostatic Hyperplasia

Prospective, Multicentre, Single-Arm Clinical Trial on the Safety and Effectiveness of Transperineal Irreversible Electroporation for the Ablation of Benign Prostatic Hyperplasia

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Sep 11, 2024

Primary completion

May 29, 2027

Study completion May 29, 2027

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Jiao Tong University Affiliated Sixth People's Hospital; The First Affiliated Hospital of University of Science and Technology of China; First People's Hospital of Hangzhou; Fujian Provincial Hospital; Zhongshan Hospital Xiamen University; Quanzhou First Hospital; Shanghai 10th People's Hospital; Shanghai Jiading District Central Hospital; Zhangzhou Municipal Hospital of Fujian Province
First posted
Mar 10, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial focuses on men with benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate causes urinary problems. The goal is to test a non-thermal ablation technique called irreversible electroporation (IRE), delivered with a steep pulse therapy system, for treating BPH. The main questions it aims to answer are: 1. How many participants have improved urine flow 3 months after treatment? 2. How do urinary symptoms, quality of life, and prostate size change after treatment? 3. What side effects occur, and how serious are they? Participants will be asked to: * undergo the IRE procedure: needle electrodes are placed in the prostate through the perineum under ultrasound guidance, and short electric pulses ablate the enlarged tissue; * attend follow-up visits at 1 and 3 months after the procedure for urine flow tests, symptom questionnaires, and ultrasound measurements.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • Composite steep-pulse therapeutic device (CNP-III)Device

    Electrodes are inserted percutaneously into the bilateral transition zones of the prostate via a transperineal approach under real-time transrectal ultrasound guidance with a biplane probe; freehand or perineal template placement is permitted by the protocol. A minimum distance of 0.5 cm is maintained from the urethra, the prostatic apex, and the rectum; needle spacing is 1.0-2.2 cm; the effective exposed electrode length is 1.5, 2.0, or 2.5 cm. Ablation is performed in the high-frequency or low-frequency mode, with ablation parameters adjusted according to the delivered current. The ablation range is assessed intraoperatively by contrast-enhanced ultrasound. Procedures are performed under general anaesthesia, neuraxial anaesthesia, or intravenous sedation combined with local anaesthesia. An indwelling urinary catheter is placed before the procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in maximum urinary flow rateTime frame: 3 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of University of Science and Technology of China

    Hefei, Anhui, China · Recruiting

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China · Recruiting

  • Quanzhou First Hospital

    Quanzhou, Fujian, China · Recruiting

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.